China Crohns Disease - Drug Forecast and Market Analysis to 2022: Industry Size, Share, Trends, Study, Analysis and Forecast

ResearchMoz.us include new market research report "PharmaPoint: Crohns Disease - China Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. Browse full report - http://www.researchmoz.us/pharmapoint-crohns-disease-china-drug-forecast-and-market-analysis-to-2022-report.html.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
ResearchMoz

ResearchMOZ

China Crohns Disease - Drug Forecast and Market Analysis to 2022

Albany, NY (PRWEB) March 21, 2014

The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).

View Full Report With TOC: http://www.researchmoz.us/pharmapoint-crohns-disease-china-drug-forecast-and-market-analysis-to-2022-report.html.

The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospiras Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Based on GlobalDatas primary research, the majority of Chinese gastroenterologists follow the ACG and/or the World Gastroenterology Organization (WGO) guidelines for the management of their CD patients. In a few cases, they also refer to the local treatment guidelines. Approximately 40% of the referrals for CD patients come from PCPs, while the rest arise from their colleagues or colorectal surgeons..

Scope:

  • Overview of Crohns disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in China from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the China Crohns disease market.

Find More Reports Related to Healthcare Category at: http://www.researchmoz.us/healthcare-market-reports-56.html.

Reasons to buy:

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Crohns disease..
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of drug performance.
  • Obtain sales forecast for drugs from 2012-2022 in China.

Related Reports:-

PharmaPoint: Crohns Disease - Canada Drug Forecast and Market Analysis to 2022

The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospiras Inflectra (infliximab) a Remicade biosimilar. Browse Full Report with TOC at: http://www.researchmoz.us/pharmapoint-crohns-disease-canada-drug-forecast-and-market-analysis-to-2022-report.html.

PharmaPoint: Crohns Disease - 5EU Drug Forecast and Market Analysis to 2022

The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).

In general, US and Canadian gastroenterologists follow the treatment guidelines published by the American College of Gastroenterology (ACG) and the American Gastroenterology Association (AGA), while physicians in the EU mainly rely on the European Crohns and Colitis Organisation (ECCO) guidelines. Outside these regions, Japanese gastroenterologists consult the guidelines published by the MHLW, while their colleagues in China and India adhere to the guidelines published by the ACG and the AGA, in addition to the guidelines issued by local medical authorities. Browse Full Report with TOC at: http://www.researchmoz.us/pharmapoint-crohns-disease-5eu-drug-forecast-and-market-analysis-to-2022-report.html.

About Us:

ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Kindly Contact:
Mrs.Sheela AK
Tel:+1-518-618-1030
Toll Free: 866-997-4948
Email: sales(at)researchmoz(dot)us
Blog: http://marketingresearchreport.wordpress.com/